New biomarkers for early disease detection, improved treatment outcomes, and mental health support emerge as key advances across neurology, oncology, and patient care.

A plasma biomarker called p-tau217 can predict cognitive decline up to a decade before symptoms appear in older adults, offering potential for early intervention in cognitive impairment and dementia.

Hypermobile Ehlers-Danlos syndrome, a connective tissue disorder, often takes over 10 years to diagnose due to wide-ranging symptoms and medical system misunderstanding, leading to serious complications and preventable harm.

High-dose oral vitamin D supplementation shows rapid improvement in skin toxicity caused by chemotherapy and radiation treatments, providing a simple intervention for cancer patients experiencing treatment-related side effects.

Regional anesthesia during surgery is associated with reduced risk of chronic post-operative pain lasting up to 12 months, according to meta-analysis findings that could change surgical pain management practices.

Researchers identified CD8+ TIGR cells, a type of gut immune cell with potential to combat inflammatory bowel disease, opening new therapeutic avenues for IBD and improving understanding of organ-specific immune regulation.

Mental health support interventions, including psychotherapy and emotional support, significantly reduce anxiety and stress in parents of infants in neonatal intensive care units, improving family outcomes during critical hospitalization periods.

Gedatolisib, a multitarget inhibitor, received approval for advanced breast cancer treatment with progression-free survival approaching 10 months in patients who failed standard CDK4/6 inhibitor and aromatase inhibitor therapies.

Preventive therapy for recurrent kidney stones yields similar results whether administered immediately or guided by urine testing, suggesting immediate treatment may be unnecessary and offering patients more flexible management options.